Latest Asset Sale News

MPower Group Limited has announced a binding agreement to sell its main renewable energy assets for approximately $19 million, reporting a net loss of $4.1 million for FY2025 largely due to discontinued operations.

Energy World Corporation Ltd reports a remarkable turnaround to a $346 million profit for FY25, driven by a $390 million gain from debt restructuring and the sale of a key Indonesian asset. The company faces funding challenges as it advances LNG and power projects in Southeast Asia.

Infinity Mining Limited’s 2025 AGM highlighted significant portfolio reshaping, including asset sales and acquisitions, alongside promising exploration results at the Cangai Copper Project.

Maggie Beer Holdings Ltd reports a transformative FY25 marked by strategic restructuring, significant cost savings, and a 3.7% sales increase excluding Paris Creek Farms. Despite EBITDA pressures from non-recurring investments, the company is positioning for sustainable profitability and growth in FY26.

DGL Group Limited reported a 3% revenue increase to $481.5 million for FY25 but swung to a $24.6 million net loss driven by asset impairments and operational challenges. The company is undertaking significant restructuring and integration efforts to restore profitability.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

Waypoint REIT delivered stable first-half earnings with a 4.7% rise in net tangible assets per security and increased its FY25 distributable earnings guidance, supported by ongoing asset sales and Viva Energy’s OTR conversions.

Waypoint REIT reported steady distributable earnings for the first half of 2025 alongside a significant rise in statutory net profit, while extending debt facilities and launching a $50 million buyback program.

The Star Entertainment Group reported a statutory net loss of $471.5 million for FY25, impacted by regulatory reforms and remediation costs, while securing a $300 million strategic investment to bolster liquidity.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.